Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy
Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy
复制标题
深入了解患有和不患有血液系统恶性肿瘤的患者的甜味综合征的特征
DOI：
10.3389/fmed.2020.00020
复制
发表时间：
2020-02-18
影响因子：
3.9
通讯作者：
Fang, Hong
中科院分区：
文献类型：
--
作者：
Zheng, Siting;Li, Sheng;Fang, Hong
背景：Sweet综合征是一种可能与恶性肿瘤，特别是血液系统恶性肿瘤有关的嗜中性皮肤病。很少有研究系统地阐述这种疾病及其与血液系统恶性肿瘤相关的特征。目的：本研究旨在描述Sweet综合征的临床病理学特征、治疗和预后，并评估与血液系统恶性肿瘤相关的患者特征。研究方法：我们回顾性分析了2010年10月至2019年2月在浙江大学附属第一医院皮肤科就诊的Sweet综合征患者。结果：该研究包括37名患者（16名男性和21名女性），平均年龄为53岁。10例患者（27%）被归类为恶性相关Sweet综合征：9例血液恶性肿瘤，包括急性髓性白血病（4/9，44%）、骨髓增生异常综合征（4/9，44%）和多发性骨髓瘤（1/9，11%），1例实体瘤诊断为肝癌。平均血红蛋白和血小板水平（分别为P = 0.007和P = 0.013），在血液系统恶性肿瘤患者显著低于那些只有Sweet综合征。恶性血液病患者与非恶性血液病患者的组织病理学无显著差异。全身性皮质类固醇是最常用的治疗（24/37，65%）。恶性血液病患者死亡率较高。总结：对于有实验室证据表明血红蛋白和血小板水平较低的Sweet综合征患者，评估其是否为血液系统恶性肿瘤非常重要。
Background: Sweet syndrome is a neutrophilic dermatosis that could be associated with malignancy, especially hematologic malignancy. Few studies have systematically elaborated on this disorder and its features related with hematologic malignancy. Objective: This study aimed to describe the clinicopathological characteristics, treatment, and outcome of Sweet syndrome and to evaluate patient characteristics associated with hematologic malignancy. Methods: We retrospectively reviewed patients with Sweet syndrome at the Department of Dermatology, the First Affiliated Hospital of Zhejiang University from October 2010 to February 2019. Results: The study included 37 patients (16 men and 21 women), with a mean age of 53 years. Ten patients (27%) were classified as having malignancy-associated Sweet syndrome: nine with a hematologic malignancy including acute myeloid leukemia (4/9, 44%), myelodysplastic syndrome (4/9, 44%), and multiple myeloma (1/9, 11%) and one with a solid tumor diagnosed with liver carcinoma. The mean hemoglobin and platelet levels (P = 0.007 and P = 0.013, respectively), were significantly lower in patients with hematologic malignancy than in those with Sweet syndrome only. No significant difference in histopathology was found between patients with and without hematologic malignancy. Systemic corticosteroids were the most frequently used treatment (24/37, 65%). Higher mortality was found in patients with hematologic malignancy. Conclusion: It is important to assess Sweet syndrome patients who have laboratory evidence of lower hemoglobin and platelet levels for a hematologic malignancy.